Anna Maria Di Giacomo

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

James Larkin, Michele Del Vecchio, Mario Mandalà et al. · Clinical Cancer Research · 2023 · 180 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments?

Luana Calabrò, Anna Maria Di Giacomo, Maresa Altomonte et al. · PubMed · 2007 · 32 citations

Medicine, Oncology, Pharmacotherapy +16

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

Michele Maio, Christian U. Blank, Andrea Necchi et al. · European Journal of Cancer · 2021 · 28 citations · Full text

Medicine, Immunology, Oncology +16

Immunotherapy for brain metastases and primary brain tumors

Anna Maria Di Giacomo, Maximilian J. Mair, Michele Ceccarelli et al. · European Journal of Cancer · 2022 · 26 citations · Full text

Medicine, Neurosurgery, Oncology +14

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

Anna Maria Di Giacomo, Michael Schenker, Jacques Médioni et al. · ESMO Open · 2024 · 10 citations · Full text

Pharmacy, Immunology, Oncology +17